Key Takeaways
- • Citron Research (led by short-seller Andrew Left) and Anson Funds Management LP face a lawsuit filed April 10, 2026, by PolarityTE investor Barry Honig over allegations of stock price manipulation and disparagement of the biotech company.
- • The plaintiff, representing himself, his company, and his family trust, alleges the hedge funds collectively owned nearly 10% of PolarityTE and made false claims about the company's patent applications and other material issues.
- • The lawsuit adds to the contentious landscape surrounding activist short selling, where negative research reports frequently trigger sharp stock price movements and subsequent legal challenges from affected shareholders.
- • The case was filed in the US District Court for the Northern District of Florida, underscoring the broader tension between short-seller disclosure obligations and investor protections in biotech equity markets.
Summary
Two prominent hedge funds—Citron Research and Anson Funds Management LP—have become defendants in a securities manipulation lawsuit filed on April 10, 2026, in federal court in Florida. The suit, brought by investor Barry Honig and his affiliated entities, alleges that the hedge funds engaged in a coordinated scheme to artificially depress the stock price of PolarityTE, a biotechnology company, through disparagement and the dissemination of false information.
According to the complaint, Honig, his company, and his family trust collectively held approximately 10% of PolarityTE's equity at the time of filing. The plaintiff claims that Citron Capital LLC, led by well-known short-seller Andrew Left, and Anson Funds made materially false assertions regarding PolarityTE's patent applications and other matters material to the company's valuation. These allegations form the basis of the stock manipulation claim.
The lawsuit exemplifies the ongoing tension between activist short-selling operations and public company shareholders. Short-seller reports—often published by firms like Citron—can trigger significant market dislocations when they challenge corporate narratives or allege misconduct. While short-sellers argue they provide important market discipline and fraud detection, affected companies and their shareholders increasingly resort to litigation to challenge the accuracy and motives behind such reports.
This case underscores broader regulatory and legal scrutiny facing the short-selling industry. As institutional investors and family offices evaluate exposure to both biotech equities and hedge fund strategies, questions surrounding short-seller accountability and disclosure standards remain contested terrain. The Florida filing signals that litigation remains a primary mechanism for disputing short-seller allegations in the absence of stronger regulatory guardrails.
According to the complaint, Honig, his company, and his family trust collectively held approximately 10% of PolarityTE's equity at the time of filing. The plaintiff claims that Citron Capital LLC, led by well-known short-seller Andrew Left, and Anson Funds made materially false assertions regarding PolarityTE's patent applications and other matters material to the company's valuation. These allegations form the basis of the stock manipulation claim.
The lawsuit exemplifies the ongoing tension between activist short-selling operations and public company shareholders. Short-seller reports—often published by firms like Citron—can trigger significant market dislocations when they challenge corporate narratives or allege misconduct. While short-sellers argue they provide important market discipline and fraud detection, affected companies and their shareholders increasingly resort to litigation to challenge the accuracy and motives behind such reports.
This case underscores broader regulatory and legal scrutiny facing the short-selling industry. As institutional investors and family offices evaluate exposure to both biotech equities and hedge fund strategies, questions surrounding short-seller accountability and disclosure standards remain contested terrain. The Florida filing signals that litigation remains a primary mechanism for disputing short-seller allegations in the absence of stronger regulatory guardrails.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.